•
Jun 30, 2020
Aytu BioScience Q4 2020 Earnings Report
Aytu BioScience's Q4 2020 financial results were announced, featuring a significant increase in net revenue and a reduced adjusted EBITDA loss.
Key Takeaways
Aytu BioScience reported a strong Q4 2020 with net revenue increasing by 766% year-over-year to $14.9 million. The company's net loss was ($3.1) million, and adjusted EBITDA loss was reduced to $1.7 million. Cash, cash equivalents, and restricted cash stood at $48.3 million.
Q4 Net Revenue increased 766% year-over-year to $14.9 million.
Q4 Consumer Health Net Revenue was $6.9 million.
Q4 Rx Net Revenue was $7.9 million.
Q4 net loss of ($3.1) million and Q4 Adjusted EBITDA of ($1.7) million.
Aytu BioScience
Aytu BioScience
Forward Guidance
Aytu BioScience anticipates continued growth and shareholder value in fiscal 2021, driven by record quarterly revenue, a narrowed Adjusted EBITDA loss, a strong cash balance, and the addition of the Healight opportunity.
Positive Outlook
- Strong momentum to grow shareholder value in fiscal 2021 and onward.
- Addition of the Healight opportunity for COVID-19 and future potential non-COVID-19 applications.
- Addition to the Russell 2000.
- Record quarterly revenue.
- Narrowed Adjusted EBITDA loss.